Shareholder Class Action

     Rigel Pharmaceuticals inflated its share price by issuing false and misleading information about clinical trials and prospects for its R788 drug, shareholders say in San Francisco Federal Court. Shareholders say share price tripled after the allegedly misleading press release.

%d bloggers like this: